U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country's biopharma sector transforms.
FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls
A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. | The FDA ...
The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and ...
President Trump’s tariffs in China are in place and hitting all products imported from the country — including a number of pharmaceutical drugs that Americans rely upon. Chinese imports ...
Impacts of tariffs on the pharmaceutical industry, cutting-edge container monitoring and the sheer number of chicken wings ...
Big Pharma is downplaying — for now — the potential negative impacts of President Donald Trump’s China tariffs on their industry. Merck (MRK) chief financial officer Caroline Litchfield told ...
Since 1994, the United States and its major trading partners have agreed to reciprocal tariff elimination for pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback